8-ethinylxanthine derivatives as selective A2A receptor antagonists
申请人:SCHWARZ PHARMA AG
公开号:EP1939197A1
公开(公告)日:2008-07-02
The present invention relates to novel 8-ethinylxanthirtes of formula (I), pharmaceutical compositions comprising such compounds, methods for preparing such compounds and methods for using these compounds, alone or in combination with other therapeutic agents for the alleviation, prevention and/or treatment of central nervous system (CNS) diseases, disorders and conditions, such as but not limited to Parkinson's disease.
Synthesis of 8-substituted xanthines via 5,6-diaminouracils: an efficient route to A2A adenosine receptor antagonists
作者:Ma Dong、Mikhail Sitkovsky、Amy E. Kallmerten、Graham B. Jones
DOI:10.1016/j.tetlet.2008.05.071
日期:2008.7
A one-pot route to 8-substituted xanthines has been developed from 5,6-diaminouracils and carboxaldehydes. The process, promoted by (bromodimethyl)sulfonium bromide, is mild and efficient and eliminates the need for external oxidants. Yields are good and the process is applicable to a range of substrates including a family of A2A adenosine receptor antagonists. Preparation of a new analog of the antagonist